Pharmacoenhancement of protease inhibitors

American Journal of Therapeutics

Volumn 13, Issue 1, 2006, Pages 57-63

  Motwani, Bharat ^a   Khayr, Walid ^a,b  

^a ROSALIND FRANKLIN UNIVERSITY OF MEDICINE AND SCIENCE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Pharmacoboosting; Pharmacoenhancement; Pharmacokinetics; Ritonavir

Indexed keywords

AMPRENAVIR; GLYCOPROTEIN P; INDINAVIR; LOPINAVIR; NELFINAVIR; PROTEINASE INHIBITOR; RITONAVIR; SAQUINAVIR;

ABDOMINAL PAIN; AREA UNDER THE CURVE; BIOAVAILABILITY; CLINICAL TRIAL; DIARRHEA; DIET RESTRICTION; DRUG BLOOD LEVEL; GASTROINTESTINAL TOXICITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NAUSEA; NEPHROLITHIASIS; PARESTHESIA; PRIORITY JOURNAL; REVIEW; STANDARDIZATION; TASTE DISORDER; VIROLOGY;

ANIMALS; CYTOCHROME P-450 ENZYME SYSTEM; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, VIRAL; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; HIV; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; P-GLYCOPROTEIN; RITONAVIR;

EID: 31544474076     PISSN: 10752765     EISSN: None     Source Type: Journal    
DOI: 10.1097/00045391-200601000-00010     Document Type: Review

References (45)

1. Ledergerber B, Egger M, Opravil M, et al. Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study. Swiss HIV Cohort Study. Lancet. 1999;353:863-868.
2. Wit FW, van Leeuwen R, Weverling GI, et al. Outcome and predictors of failure of highly active antiretroviral therapy: one-year follow-up of a cohort of human immunodeficiency virus type 1 infected persons. J Infect Dis. 1999;179:790-798.
3. Moyle GJ. Use of HIV protease inhibitors as pharmacoenhancers. AIDS Read. 2001;11:87-98.
4. Back D, Gatti G, Fletcher C, et al. Therapeutic drug monitoring in HIV infection: current status and future directions. AIDS. 2002;16(suppl):S5-S37.
5. Kempf DJ, Marsh KC, Kumar G, et al. Pharmacokinetic enhancement of inhibitors of the human immunodeficiency virus protease by coadministration with ritonavir. Antimicrob Agents Chemother. 1997;41:654-660.
6. van Heeswijk RP, Veldkamp A, Mulder JW, et al. Combination of protease inhibitors for the treatment of HIV-1-infected patients: a review of pharmacokinetics and clinical experience. Antivir Ther. 2001;6:201-229.
7. Rathbun RC, Rossi DR. Low-dose ritonavir for protease inhibitor pharmacokinetic enhancement. Ann Pharmacother. 2002;36:702-706.
8. Washington CB, Duran GE, Man MC, et al. Interaction of anti-HIV protease inhibitors with the multidrug transporter P-glycoprotein in human cultured cells. J Acquir Immune Defic Syndr Hum Refroviral. 1998;19:203-209.
9. Kim RB, Fromm MF, Wandel C, et al. The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors. J Clin Invest. 1998;101:289-294.
10. Nascimbent M, Lamotte C, Peytavin G, et al. Kinetics of antiviral activity and intracellular pharmacokinetics of human immunodeficiency virus type 1 protease inhibitors in tissue culture. Antimicrob Agents Chemother. 1999;43:2629-2634.
11. Molla A, Korneyeva M, Gao Q, et al. Ordered accumulation of mutations in HIV protease confers resistance to ritonavir. Nat Med. 1996;2:760-766.
12. Castagna A, Danise A, Hasson H, et al. The normalized inhibitory quotient (NIQ) of lopinavir is predictive of viral load response over 48 weeks in a cohort of highly experienced HIV-1 infected individual [abstract 128]. In: 9th Conference on Retroviruses and Opportunistic infections (Seattle). Alexandria, VA: Foundation for Retroviruses and Human Health; 2002.
13. Condra JH, Petropoulos CJ, Ziermann R, et al. Drug resistance and predicted virologic response to human immunodeficiency virus type 1 protease inhibitor therapy. J Infect Dis. 2000;182:758-765.
14. Parks D, Rogers M, Hazen R, et al. Forgiveness quotient: method for evaluating the advantage of ritonavir-induced pharmacokinetic boosting of HIV protease inhibitors [abstract 82]. Presented at the DART meeting, San Juan, Puerto Rico, 2000.
15. Sham HL, Kempf DJ, Molla A, et al. ABT-378, a highly potent inhibitor of the human immunodeficiency virus protease. Antimicrob Agents Chemother. 1998;42:3218-3224.
16. Saah AJ, Winchell G, Seniuk M, et al. Multiple dose pharmacokinetics (PK) and tolerability of indinavir (IDV) ritonavir combinations in healthy volunteers [abstract 362]. Presented at the 6th Conference on Retroviruses and Opportunistic Infections, Chicago, 1999.
17. Hsu A, Chi YI, Hutman W, et al. Pharmacokinetic interactions between ritonavir and amprenavir in healthy volunteers [abstract WeOrB546]. Presented at the XIII International AIDS Conference, Durban, South Africa, 2000.
18. Geischke R, Fotteler B, Buss N, et al. Relationships between exposure of saquinavir monotherapy and antiviral response in HIV-positive patients. Clin Pharmacokinet. 1999;37:75-86.
19. van Heeswijk RP, Veldkamp AI, Hoetelmans RM, et al. The steady state plasma pharmacokinetics of indinavir alone and in combination with a low dose of ritonavir in twice daily dosing regimens in HIV-1 infected individuals. AIDS. 1999;13:F95-F99.
20. Veldkamp AI, van Heeswijk RP, Mulder JW, et al. Steady-state pharmacokinetics of twice-daily dosing of saquinavir plus ritonavir in HIV-1 infected individuals. J Acquir Immune Defic Syndr. 2001;27:344-349.
21. Kilby JM, Sfakianos G, Gizzi N, et al. Safety and pharmacokinetics of once-daily regimens of soft-gel capsule saquinavir plus minidose ritonavir in human immuno-deficiency virus-negative adults. Antimicrob Agents Chemother. 2000;44:2672-2678.
22. Cooper CL, van Heeswijk RP, Gallicano K, et al. A review of low-dose ritonavir in protease inhibitor combination therapy. Clin Infect Dis. 2003;36:1585-1592.
23. Cardiello PG, van Heeswijk RP. Hassink Ea et al. Simplifying protease inhibitor therapy with once-daily dosing of saquinavir soft-gelatin capsules/ritonavir (1600/100mg): HIVNAT001.3 study. J Acquir Immune Defic Syndr. 2002;29:464-470.
24. Burger DM, Hugen PW, van der Ende ME, et al. Once-daily Indinavir plus ritonavir: preliminary results of the PIPO study. AIDS. 2000;14:2621-2623.
25. Hugen PW, Burger DM, ter Hofstede HJ, et al. Dose-finding study of a once daily indinavir/ritonavir regimen. J Acquir Immune Defic Syndr. 2000;25:236-245.
26. Bartlett JA, Johnson J, Herrera G, et al. Abacavir/lamivudine (ABC/3TC) in combination with efavirenz (NNRTI), amprenavir/ritonavir (PI) or stavudine (NRTI): ESS4001 (CLASS) preliminary 48 week results. Presented at the XIVth International AIDS Conference, Barcelona, Spain, 2002.
27. Walmsley S, Bernstein B, King M, et al. Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection. N Engl J Med. 2002;346:2039-2046.
28. Dragsted UB, Gerstoft J, Pedersen C, et al. Randomized trial to evaluate indinavir/ritonavir versus saquinavir/ritonavir in human immunodeficiency virus type 1 infected patients: the MaxCmin1 Trial. J Infect Dis. 2003;188:635-642.
29. Feinberg JE, Eron JJ, Bernstein B, et al. Once-daily versus twice-daily Kaletra (lopinavir/ritonavir) in antiretroviral naïve HIV+ patients: 72 week follow-up [abstract Tu- PeB4445]. In: 14th International AIDS Conference (Barcelona). Barcelona: Prous Science Sa; 2002.
30. US Prescribing Information. Norvir (ritonavir capsules) soft gelatin. Chicago, IL: Abbott Laboratories; 2000.
31. Sulkowski MS, Thomas DL, Chaisson RE, et al. Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection. JAMA. 2000;283:74-80.
32. Cameron DW, Heath-Chiozzi M, Danner S, et al. Randomized placebo-controlled trial of ritonavir in advanced HIV-1 disease. The Advanced HIV Disease Ritonavir Study Group. Lancet. 1998;351:543-549.
33. Gerstoft J, Mallolas J, Lundgren J, et al. A randomized trial comparing continued Indinavir vs. switching to Indinavir plus ritonavir in HIV patients having suppressed viral load with Indinavir plus two nucleoside analogue reverse transcriptase inhibitors: the best study [abstract O-8]. In: Program and abstracts of the 8th European Conference on Clinical Aspects and Treatment of HIV infection Athens. Athens: Provoli Punlicity SA; 2001.
34. Cameron DW, Japour AJ, Xu Y, et al. Ritonavir and saquinavir combination therapy for the treatment of HIV infection. AIDS. 1999;13:213-224.
35. Sadler CA, Piliero PJ, Preston SL, et al. Pharmacokinetic (PK) drug-interaction between amprenavir (APV) and ritonavir (RTV) in HIV seronegative subjects after multiple oral dosing [abstract 77]. Presented at the 7th Conference on Retroviruses and Opportunistic Infections. San Francisco, 2000.
36. Luber AD, Stryker R, Burdick J, et al. Efficacy of amprenavir (APV) 600mg plus low-dose ritonavir (RTV) in clinical practice [abstract P40]. AIDS. 2000;14 (suppl 4):S28.
37. Casado JL, Moreno A, Marti-Belda P, et al. Increased indinavir levels using twice daily ritonavir/indinavir at 100/800mg improves virologic response even after multiple failure [abstract 1170]. Presented at the 40th Inter-science Conference on Antimicrobial Agents and Chemotherapy. Toronto, Canada; 2000.
38. Burger DM, Hugen PW, Aarnoutse RE, et al. A retrospective, cohort-based survey of patients using twice-daily indinavir plus ritonavir combinations: pharmacokinetics, safety, and efficacy. J Acquir Immune Defic Syndr Hum Retrovirol. 2001;26:218-224.
39. Dielman JP, Salahuddin S, Hsu YS, et al. Indinavir crystallization around the loop of Henle: experimental evidence. J Acquir Immune Defic Syndr. 2001;28:9-13.
40. Chaillou S, Durant J, Clevenbergh P, et al. Does ritonavir 'baby dose' induce specific mutations in salvage combination therapy? A Viradapt sub study [abstract 1267]. Presented at the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy. Toronto, Canada, 2000.
41. Deeks S, Brun S, Xu Y, et al. ABT-378/ritonavir (ABT-378/R) suppresses HIV RNA to, 400 copies/mL in 84% of PI-experienced patients at 48 weeks [abstract 532]. In: Program and abstracts of the 7th Conference on Retroviruses and Opportunistic Infection (San Francisco). Alexandria, VA: Foundation for Retroviruses and Human Health; 2000.
42. Montaner J, Saag MS, Barylski C, et al. FOCUS study: saquinavir QD regimen versus efavirenz QD regimen 48 week analysis in HIV infected patients [abstract H-167]. In: Program and abstracts of the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy (San Diego). Washington, DC: American Society for Microbiology; 2002.
43. Piketty C, Race E, Castiel P, et al. Efficacy of a five-drug combination including ritonavir, saquinavir and efavirenz in patients who failed on a conventional triple-drug regimen: phenotypic resistance to protease inhibitors predicts outcome of therapy. AIDS. 1999;13:F71-F77.
44. O'Brien WA, Atkinson TL, Han X. Combination therapy with Indinavir and Ritonavir in antiretroviral treatment experienced patients [abstract 2209]. In: Program and abstracts of the 39th Interscience Conference on Antimicrobial Agents and Chemotherapy (San Francisco). Washington, DC: American Society for Microbiology; 1999.
45. Campo R, Suarez G, Miller N. Efficacy of indinavir/ritonavir based regimens among patients with prior protease inhibitor failure [abstract]. Antivir Ther. 2000;5(suppl 2):27.